JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

REVOLUTION Medicines Inc

Cerrado

SectorSanidad

54.31 1.63

Resumen

Variación precio

24h

Actual

Mínimo

54.31

Máximo

55.3

Métricas clave

By Trading Economics

Ingresos

-34M

-248M

Margen de beneficios

-74.379

Empleados

700

EBITDA

-24M

-261M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+42.35% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

3.2B

10B

Apertura anterior

52.68

Cierre anterior

54.31

Noticias sobre sentimiento de mercado

By Acuity

14%

86%

18 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

REVOLUTION Medicines Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 oct 2025, 18:13 UTC

Principales Movimientos del Mercado

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

Comparación entre iguales

Cambio de precio

REVOLUTION Medicines Inc previsión

Precio Objetivo

By TipRanks

42.35% repunte

Estimación a 12 Meses

Media 76.07 USD  42.35%

Máximo 90 USD

Mínimo 66 USD

De acuerdo con 17 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para REVOLUTION Medicines Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

17 ratings

17

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

40.67 / 41.96Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

18 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
help-icon Live chat